Interim guidance issued for evaluating patients with suspected vaping-associated lung injury

A guidance document has been issued to provide interim recommendations for healthcare providers evaluating and caring for patients with suspected e-cigarette, or vaping, product use-associated lung injury. The document does not report specific study type, phase, sample size, or setting. No intervention, comparator, or primary or secondary outcomes are detailed.

No main results, including specific clinical outcomes or efficacy data, are reported. Safety and tolerability information, including adverse events, serious adverse events, and discontinuations, are also not reported. The document does not list specific methodological limitations.

The practice relevance is explicitly stated as providing interim guidance for clinicians. Funding sources and potential conflicts of interest are not reported. This guidance should be viewed as a preliminary clinical tool based on available information at the time of publication, not as a definitive standard of care derived from a formal evidence review.